Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.033969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Yuya Sudo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Kagawa Prefectural Central Hospital Takamatsu Kagawa Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Eicosapentaenoic Acid, Catheter Ablation, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
A lower serum eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA) level correlates with cardiovascular events. Nevertheless, elevated serum EPA levels increase the risk of new‐onset atrial fibrillation (AF) in older patients. The relationship between the EPA/AA and outcomes post‐AF ablation remains unclear. This study investigated the impact of the EPA/AA on AF recurrence and cardiovascular events after AF ablation in older patients. Methods and Results This retrospective cohort study examined consecutive patients with AF aged ≥65 years who underwent a first‐time AF ablation. We compared the 3‐year AF recurrence and 5‐year major adverse cardiovascular event (MACE) rates between patients divided into high and low EPA/AA levels defined as above and below the median EPA/AA value before ablation. MACE was defined as heart failure hospitalizations, strokes, coronary artery disease, major bleeding, and cardiovascular death. Among the 673 included patients, the median EPA/AA value was 0.35. Compared with the low EPA/AA group, the high EPA/AA group had a significantly higher cumulative incidence of AF recurrence (39.3% versus 27.6%; log‐rank P =0.004) and lower cumulative incidence of MACE (13.8% versus 25.5%, log‐rank P =0.021). A high EPA/AA level was determined as an independent predictor of AF recurrence (hazard ratio [HR], 1.75 95% CI, 1.24–2.49; P =0.002) and MACE (HR, 0.60 [95% CI, 0.36–0.99]; P =0.046).
Conclusions
The EPA/AA was associated with AF recurrence and MACE after ablation in patients with AF aged ≥65 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine Kagawa Prefectural Central Hospital Takamatsu Kagawa Japan.
- Department of Data Science/Clinical Epidemiology Hyogo Medical University Nishinomiya Hyogo Japan.
ORCID-Profile: Yuya Sudo, Takeshi Morimoto, Akihiro Oka, Masahiro Sogo, Masatomo Ozaki, Masahiko Takahashi, Keisuke Okawa
Zitieren
APA
Sudo, Y., Morimoto, T., Tsushima, R., Oka, A., Sogo, M., Ozaki, M., Takahashi, M., & Okawa, K. (2024). Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033969
Vancouver
Sudo Y, Morimoto T, Tsushima R, Oka A, Sogo M, Ozaki M, et al. Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033969
BibTeX
@article{Sudo2024,
author = {Sudo, Yuya and Morimoto, Takeshi and Tsushima, Ryu and Oka, Akihiro and Sogo, Masahiro and Ozaki, Masatomo and Takahashi, Masahiko and Okawa, Keisuke},
title = {Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.033969}
}
EUVIMED